Segment Information (Tables)

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Schedule of Financial Information by Segment

Financial information by segment is as follows:

	Year Ended December 31, 2021
	Cell Therapy			BioBanking			Degenerative Disease		Other				Total
Net revenues	$	—		$	5,522		$	15,813	$	—			$	21,335
Gross profit		—			1,873			9,809		—				11,682
Direct expenses		85,107			2,119			8,450		64,017				159,693
Segment contribution		(85,107	)		(246	)		1,359		(64,017	)			(148,011	)
Indirect expenses										(38,953	)	(a)	$	(38,953	)
Loss from operations														(109,058	)
(a) Components of other
Change in fair value of contingent consideration    liability										(41,145	)
Amortization										2,192
Total other									$	(38,953	)

	Year Ended December 31, 2020
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net revenues	$	—		$	5,556	$	8,722		$	—			$	14,278
Gross profit		—			3,262		6,084			—				9,346
Direct expenses		51,470			1,653		10,348			20,573				84,043
Segment contribution		(51,470	)		1,609		(4,264	)		(20,573	)			(74,697	)
Indirect expenses										77,228		(a)	$	77,228
Loss from operations														(151,925	)
(a) Components of other
Change in fair value of contingent consideration    liability										(55,566	)
Impairment of acquired intangible assets										129,400
Amortization										3,394
Total other									$	77,228